Stock Track | Intellia Therapeutics Plummets 5% Following Wolfe Research Downgrade Over Nex-z Safety Concerns

Stock Track11-13

Intellia Therapeutics (NTLA) saw its stock price plummet by 5.01% during Wednesday's trading session, following a significant downgrade by Wolfe Research. The sharp decline comes as investors react to growing concerns over the safety profile of one of the company's key products.

Wolfe Research, in a notable shift, downgraded Intellia Therapeutics from Outperform to Peer Perform. The downgrade was primarily attributed to safety issues surrounding Nex-z, which is likely a crucial drug or treatment in Intellia's pipeline. This change in rating suggests a more cautious stance from analysts regarding the company's near-term prospects.

The downgrade and subsequent stock decline highlight the sensitivity of biotech stocks to clinical development setbacks, especially those related to safety concerns. Investors will be closely watching for any further updates from Intellia Therapeutics regarding the Nex-z safety issue and its potential impact on the company's development timeline and overall strategy.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1175854006?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 00:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1175854006","market":"us","top_or_hot":-1,"title":"Stock Track | Intellia Therapeutics Plummets 5% Following Wolfe Research Downgrade Over Nex-z Safety Concerns","media":"Stock Track","content":"<p>Intellia Therapeutics (NTLA) saw its stock price plummet by 5.01% during Wednesday's trading session, following a significant downgrade by Wolfe Research. The sharp decline comes as investors react to growing concerns over the safety profile of one of the company's key products.</p>\n\n<p>Wolfe Research, in a notable shift, downgraded Intellia Therapeutics from Outperform to Peer Perform. The downgrade was primarily attributed to safety issues surrounding Nex-z, which is likely a crucial drug or treatment in Intellia's pipeline. This change in rating suggests a more cautious stance from analysts regarding the company's near-term prospects.</p>\n\n<p>The downgrade and subsequent stock decline highlight the sensitivity of biotech stocks to clinical development setbacks, especially those related to safety concerns. Investors will be closely watching for any further updates from Intellia Therapeutics regarding the Nex-z safety issue and its potential impact on the company's development timeline and overall strategy.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Intellia Therapeutics Plummets 5% Following Wolfe Research Downgrade Over Nex-z Safety Concerns</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Intellia Therapeutics Plummets 5% Following Wolfe Research Downgrade Over Nex-z Safety Concerns\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-13 00:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Intellia Therapeutics (NTLA) saw its stock price plummet by 5.01% during Wednesday's trading session, following a significant downgrade by Wolfe Research. The sharp decline comes as investors react to growing concerns over the safety profile of one of the company's key products.</p>\n\n<p>Wolfe Research, in a notable shift, downgraded Intellia Therapeutics from Outperform to Peer Perform. The downgrade was primarily attributed to safety issues surrounding Nex-z, which is likely a crucial drug or treatment in Intellia's pipeline. This change in rating suggests a more cautious stance from analysts regarding the company's near-term prospects.</p>\n\n<p>The downgrade and subsequent stock decline highlight the sensitivity of biotech stocks to clinical development setbacks, especially those related to safety concerns. Investors will be closely watching for any further updates from Intellia Therapeutics regarding the Nex-z safety issue and its potential impact on the company's development timeline and overall strategy.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NTLA","symbol_name":"Intellia Therapeutics Inc","start_time":0,"source_url":"","article_id":"1175854006","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1175854006","pubTimestamp":1762966104,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Intellia Therapeutics (NTLA) saw its stock price plummet by 5.01% during Wednesday's trading session, following a significant downgrade by Wolfe Research. The sharp decline comes as investors react...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NTLA":"Intellia Therapeutics Inc"},"translate_title":"个股追踪|Wolfe Research因Nex-z安全担忧下调评级后Intellia Therapeutics暴跌5%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NTLA":1},"content_text":"Intellia Therapeutics (NTLA) saw its stock price plummet by 5.01% during Wednesday's trading session, following a significant downgrade by Wolfe Research. The sharp decline comes as investors react to growing concerns over the safety profile of one of the company's key products.\nWolfe Research, in a notable shift, downgraded Intellia Therapeutics from Outperform to Peer Perform. The downgrade was primarily attributed to safety issues surrounding Nex-z, which is likely a crucial drug or treatment in Intellia's pipeline. This change in rating suggests a more cautious stance from analysts regarding the company's near-term prospects.\nThe downgrade and subsequent stock decline highlight the sensitivity of biotech stocks to clinical development setbacks, especially those related to safety concerns. Investors will be closely watching for any further updates from Intellia Therapeutics regarding the Nex-z safety issue and its potential impact on the company's development timeline and overall strategy.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1175854006","isCrawlerRequest":true}